Industry News

In recent weeks several major drugmakers have stopped providing 340B pricing for safety net hospitals

More than 1,100 hospitals have sent a letter to Health and Human Services Secretary Alex Azar demanding that the department enforce 340B drug pricing requirements. In recent weeks several major drugmakers have stopped providing 340B pricings for safety net hospitals. First, AstraZeneca announced it would stop offering discounts for 340B drugs beginning October 1. Then, Eli Lilly cut off discounts for the drugs, with a limited exception for insulin products. Read More

Healthcare Finance | September 11, 2020

Drugmakers getting bolder in fight over 340B drug discounts

Drugmakers are getting bolder in their bid to restrict access to drugs discounted under the 340B program as legal experts say a lack of enforcement has created a regulatory void. Hospitals are imploring the Department of Health and Human Services (HHS) to clamp down on several moves by drug companies, including Novartis and AstraZeneca, to limit distribution of certain 340B drugs. But experts say an administration-wide change in what agencies can enforce is likely behind drugmakers’ aggressive moves. Read More

Fierce Healthcare | August 26, 2020

Appeals court upholds nearly 30% payment cut to 340B hospitals

A federal appeals court has ruled the Trump administration can install nearly 30% cuts to the 340B drug discount program. The ruling Friday is the latest legal setback for hospitals that have been vociferously fighting cuts the Department of Health and Human Services (HHS) announced back in 2017. Read More

Fierce Healthcare | July 31, 2020

HRSA Announces New Registration and Recertification Requirements for 340B Program

The Office of Pharmacy Affairs (OPA) of the Health Resources and Services Administration (HRSA) recently issued a new Program Update that includes new covered entity registration and recertification requirements, as well as enhancements to the 340B Office of Pharmacy Affairs Information System (OPAIS). HRSA may be implementing these new registration requirements in order to identify and potentially take action against covered entities that HRSA believes do not qualify under a 340B covered entity category and to provide additional information to states and drug manufacturers necessary to identify and recoup duplicate discounts.Read More

National Law Review | July 22, 2020

Federal Court Blocks Medicare 340B Cuts

A federal court has found the Department of Health & Human Services (HHS) exceeded its authority by making deep cuts to Medicare Part B drug payments to many 340B hospitals. The decision marks a major victory for hospitals and their patients. Read More

340B Informed | December 28. 2018

Campaign Launched Against PhRMA’s Proposal to Raise Drug Costs on America’s Seniors

An ad campaign launched today on President Trump’s favorite television morning news program urges the President to reject proposed changes to a vital federal drug discount program that would undo one of his greatest domestic policy achievements – providing America’s senior citizens with hundreds of millions of dollars of savings on prescription drugs. Read More

340B Matters | November 13, 2018

HHS awards $293 million to expand primary health care workforce

Today, the U.S. Department of Health and Human Services (HHS) Health Resources and Services Administration (HRSA) announced $293 million in awards to primary health care clinicians and students through the National Health Service Corps (NHSC) and Nurse Corps programs. Read More

HRSA Press Office | October 18, 2018